Heron Therapeutics | HRTX - Заемный капитал





Заемный капитал Изменить Дата
ALKERMES USD 285.82M 639K 2024-09
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
ANI Pharmaceuticals USD 291.84M 5.84M 2025-12
Arrowhead Research USD 538.1M 323.22M 2025-12
Eisai JPY 134.77B 12M 2025-12
Emergent BioSolutions USD 446.5M 1.7M 2023-12
Esperion Therapeutics USD 457.65M 9.5M 2025-12
GlaxoSmithKline GBP 14.01B 696M 2026-03
Heron Therapeutics USD 140.64M 975K 2025-12
Insmed USD 540.96M 1.24M 2025-12
Ligand Pharmaceuticals USD 445.49M 445.44M 2025-09
Merck USD 46.67B 77M 2026-03
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Omeros USD 403.72M 27.2M 2024-06
Pacira USD 367.66M 4.53M 2026-03
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sangamo BioSciences USD 0 0 2022-06
Surmodics USD 29.67M 116K 2025-06
Ultragenyx Pharmaceutical USD 1.15B 383.26M 2025-12
Veracyte USD 0 0 2025-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12